FY2024 EPS Estimates for Neurogene Boosted by HC Wainwright

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for Neurogene in a research note issued on Tuesday, November 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($4.34) for the year, up from their previous forecast of ($4.42). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.19) EPS.

A number of other research analysts have also weighed in on the company. Stifel Nicolaus raised their price objective on Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Leerink Partners raised their price target on Neurogene from $45.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. BMO Capital Markets decreased their price objective on Neurogene from $60.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday. Robert W. Baird raised their target price on shares of Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neurogene in a research note on Tuesday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $60.83.

Neurogene Stock Up 30.2 %

NGNE opened at $20.30 on Thursday. The company has a fifty day moving average of $44.97 and a 200 day moving average of $39.53. Neurogene has a fifty-two week low of $12.49 and a fifty-two week high of $74.49.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NGNE. RTW Investments LP raised its stake in shares of Neurogene by 6.0% in the third quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock valued at $47,635,000 after acquiring an additional 64,691 shares during the period. FMR LLC raised its position in Neurogene by 912.4% in the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after purchasing an additional 659,515 shares during the period. Vanguard Group Inc. lifted its stake in Neurogene by 906.5% in the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock worth $25,831,000 after purchasing an additional 457,062 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in Neurogene by 0.6% in the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock worth $23,211,000 after purchasing an additional 2,499 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Neurogene by 17.5% during the third quarter. State Street Corp now owns 246,540 shares of the company’s stock valued at $10,345,000 after buying an additional 36,687 shares during the period. 52.37% of the stock is owned by hedge funds and other institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.